[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2001274562A1 - Ligand to gpr8 and dna thereof - Google Patents

Ligand to gpr8 and dna thereof

Info

Publication number
AU2001274562A1
AU2001274562A1 AU2001274562A AU7456201A AU2001274562A1 AU 2001274562 A1 AU2001274562 A1 AU 2001274562A1 AU 2001274562 A AU2001274562 A AU 2001274562A AU 7456201 A AU7456201 A AU 7456201A AU 2001274562 A1 AU2001274562 A1 AU 2001274562A1
Authority
AU
Australia
Prior art keywords
gpr8
ligand
dna
present
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001274562A
Inventor
Michiko Abe
Yuka Adachi
Taiji Asami
Mioko Harada
Chieko Kitada
Mika Kurihara
Yoshio Matsumoto
Masaaki Mori
Yukio Shimomura
Tsukasa Sugo
Takuya Watanabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of AU2001274562A1 publication Critical patent/AU2001274562A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention aims at providing a ligand to GPR8, its DNA, etc., and more particularly, a polypeptide capable of binding to GPR8 or its amides or esters, or salts thereof, as well as its DNA, etc. The ligand to GPR8 of the present invention is useful in developing a receptor-binding assay system with the use of a GPR8 expression system, screening candidate compounds for drugs such as preventive/therapeutic agents for obesity, appetite stimulants, prolactin production inhibitors, etc.
AU2001274562A 2000-06-21 2001-06-20 Ligand to gpr8 and dna thereof Abandoned AU2001274562A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2000-191089 2000-06-21
JP2000191089 2000-06-21
JP2000-275013 2000-09-06
JP2000275013 2000-09-06
JP2001116000 2001-04-13
JP2001-116000 2001-04-13
PCT/JP2001/005257 WO2001098494A1 (en) 2000-06-21 2001-06-20 Ligand to gpr8 and dna thereof

Publications (1)

Publication Number Publication Date
AU2001274562A1 true AU2001274562A1 (en) 2002-01-02

Family

ID=27343845

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001274562A Abandoned AU2001274562A1 (en) 2000-06-21 2001-06-20 Ligand to gpr8 and dna thereof

Country Status (7)

Country Link
US (2) US7193033B2 (en)
EP (1) EP1293567B1 (en)
AT (1) ATE437949T1 (en)
AU (1) AU2001274562A1 (en)
CA (1) CA2413195C (en)
DE (1) DE60139399D1 (en)
WO (1) WO2001098494A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1394543B1 (en) * 2001-05-15 2007-08-29 Takeda Pharmaceutical Company Limited Screening method
EP1403281B1 (en) 2001-06-14 2008-07-09 Takeda Pharmaceutical Company Limited Novel ligand and dna thereof
AU2002362165A1 (en) * 2001-12-28 2003-07-24 Takeda Chemical Industries, Ltd. Body weight gain inhibitor
WO2003081234A2 (en) * 2002-03-26 2003-10-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with homo sapiens g - protein - coupled receptor 8 (gpr8)
WO2003082907A1 (en) * 2002-03-29 2003-10-09 Euroscreen Sa Ligands for g protein coupled receptor gpr7 and uses thereof
WO2004041301A1 (en) * 2002-11-06 2004-05-21 Takeda Pharmaceutical Company Limited Antidiuretics
EP1602380A4 (en) * 2003-03-13 2009-09-02 Takeda Chemical Industries Ltd Preventive/remedy for diseases in upper digestive tract
EP1627888A4 (en) * 2003-05-28 2007-04-18 Takeda Pharmaceutical ANTIBODIES AND ITS USE
JP4504098B2 (en) * 2003-05-28 2010-07-14 武田薬品工業株式会社 Antibodies and their uses
WO2008073578A2 (en) 2006-12-08 2008-06-19 Iowa State University Research Foundation, Inc. Plant genes involved in nitrate uptake and metabolism
JP2010539032A (en) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト Use of BUBUC and optional EAA-MART1 (26-35) as a therapeutic agent for HCMV infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5591602A (en) * 1993-11-05 1997-01-07 O'dowd; Brian F. Nucleic acid encoding opioid receptor
JPH09121865A (en) 1995-10-30 1997-05-13 Takeda Chem Ind Ltd New g-protein-coupled type receptor protein, its production and use thereof
US6555339B1 (en) 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
WO2002008417A1 (en) * 2000-07-25 2002-01-31 Takeda Chemical Industries, Ltd. Process for producing recombinant protein
EP1344823A4 (en) 2000-11-30 2005-03-16 Takeda Chemical Industries Ltd Novel g protein-coupled receptor proteins and dnas thereof
EP1394543B1 (en) 2001-05-15 2007-08-29 Takeda Pharmaceutical Company Limited Screening method

Also Published As

Publication number Publication date
US20080305998A1 (en) 2008-12-11
US7671174B2 (en) 2010-03-02
EP1293567A1 (en) 2003-03-19
CA2413195C (en) 2012-01-17
US20050153391A1 (en) 2005-07-14
EP1293567B1 (en) 2009-07-29
CA2413195A1 (en) 2002-12-17
EP1293567A4 (en) 2005-02-16
WO2001098494A1 (en) 2001-12-27
DE60139399D1 (en) 2009-09-10
ATE437949T1 (en) 2009-08-15
US7193033B2 (en) 2007-03-20

Similar Documents

Publication Publication Date Title
AU2001274562A1 (en) Ligand to gpr8 and dna thereof
BG104819A (en) Substituted indolealkanoic acids
DE60301491D1 (en) Acc-hemmer
UA84025C2 (en) Normal;heading 1;heading 2;2-(QUINOXALIN-5-YLSULFONYLAMINO)-BENZAMIDE COMPOUNDS AS CCK2 MODULATORS
YU84403A (en) Compounds useful as intermediates for derivates-4-aminochinoline
DK15589D0 (en) CHEMICAL COMPOUNDS
BR0007035A (en) Pest control methods for agrotides
MY134167A (en) Biphenylcarboxamides useful as lipid lowering agents
AU4981500A (en) Cancer treatment with endothelin receptor antagonists
GB9924957D0 (en) Novel treatment
SE8801275D0 (en) NEW USES OF DOPAMINE AGONISTS
ID23053A (en) CARBOXAMIDE USED AS A 5-HT <IF> AGONIST
AP2001002377A0 (en) Substituted phenoxyacetic acids.
ITMI20020773A1 (en) DRUGS FOR THE TREATMENT OF ARTHRITIS
EP1422240A3 (en) Analogs of nociceptin
ATE548350T1 (en) N-ARYLPIPERIDINE-SUBSTITUTED BIPHENYL CARBONIC ACID AMIDES AS INHIBITORS OF APOLIPOPROTEIN B
DE60332579D1 (en) Process for immobilizing polypeptides via the carboxyl group of the C-terminus
EP1569634B8 (en) Use of a ppar-alpha agonist and metformin for the treatment of obesity
AU1559501A (en) Apoptosis inducing proteinaceous substance
AU669149B2 (en) Expression signal-peptide-free staphylokinases
WO2002102847A1 (en) Novel ligand and dna thereof
WO2001004354A3 (en) Use of ras inhibitors of inhibiting muscle atrophy
DE60032161D1 (en) P-GLYCOPROTEINS AND ITS USES
SE9701409D0 (en) Treatment of rheumatoid arthritis
WO2003083099A3 (en) Purified polypeptides involved in protein synthesis and modification